文献速递淋巴瘤

中低收入国家背景下儿童伯基特淋巴瘤资源适应性管理策略及结局:印度单中心经验

Resource-adapted strategies in the management of paediatric Burkitt lymphoma in low- and middle-income country setting and outcomes: An Indian centre experience.
PubMed 文献 · Br J Haematol · 2025-04-22

该研究回顾性分析2007-2017年印度单中心85例≤14岁伯基特淋巴瘤患儿,采用COMP、MCP 842或修改版LMB 96方案分层治疗,4年无事件生存率和总生存率分别为72.9%和74.1%,晚期疾病和肿瘤溶解综合征为 inferior EFS 的显著预测因素,通过合理使用单剂拉布立酶和调整剂量甲氨蝶呤可在资源有限条件下获得较好生存。

要点

  • 85例患儿中78%为晚期疾病(III期33例,IV期25例),腹部为最常见原发部位(56%)。
  • 4年OS按A、B、C组分别为100%、73.2%、56%(p=0.005)。
  • 多因素分析显示晚期疾病和肿瘤溶解综合征是EFS不良的显著预测因素。

核心结论

  • 在资源有限条件下,通过合理使用单剂拉布立酶和调整剂量甲氨蝶呤,可获得较好的生存结局。
  • 晚期疾病和肿瘤溶解综合征是多因素分析中EFS不良的显著预测因素。

研究设计与样本

  • 回顾性分析2007-2017年印度单中心85例≤14岁伯基特淋巴瘤患儿,中位年龄6.5(2-12)岁。
  • A、B、C组疾病分别占22%、48%、30%;晚期疾病占78%(III期33例,IV期25例),I期6例,II期21例。
  • 最常见原发部位为腹部(56%);10例有中枢神经系统受累,22例有骨髓受累。
  • A组采用COMP方案(英国儿童癌症研究组),B和C组采用MCP 842方案(2007-2008年)或修改版LMB 96方案(2009-2017年)。
  • 17例发生肿瘤溶解综合征;22例(25%)死亡,其中6例死于肿瘤溶解综合征,4例死于感染,12例死于疾病。

主要发现

  • 4年无事件生存率和总生存率分别为72.9%和74.1%。
  • 4年OS按A、B、C组分别为100%、73.2%、56%(p=0.005)。
  • 4年OS按I、II、III、IV期分别为100%、90.5%、72.7%、56%(p=0.02)。
  • 多因素分析显示晚期疾病和肿瘤溶解综合征是EFS不良的显著预测因素。

临床怎么用

  • 原文结论认为在资源有限条件下,通过合理使用单剂拉布立酶和调整剂量甲氨蝶呤可获得较好的生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Burkitt lymphoma (BL) is a challenging cancer to treat in resource-limited settings. We retrospectively analysed 85 BL children ≤14 years, treated during 2007-2017. Median age was 6.5 (2-12) years. Group A, B and C disease was seen in 22%, 48% and 30% respectively. Advanced disease was seen in 78% (stage III 33, stage IV 25). Six children had stage I and 21 had stage II disease. The commonest primary site was the abdomen (56%). Ten children had central nervous system (CNS) and 22 had marrow involvement. Treatment protocols included cyclophosphamide, oncovin, methotrexate, prednisolone (COMP) (United Kingdom Childhood Cancer Study Group) for group A and Multi Centre Protocol 842 (MCP 842) (2007-2008)/modified Lymphomes Malins de Burkitt (LMB) 96 (2009-2017) for group B and C disease. Seventeen children developed tumour lysis syndrome (TLS). Twenty-two children (25%) expired, six from TLS, four from infection and 12 due to disease. Median follow-up was 8.6 (4-15) years. Four-year event-free survival (EFS) and overall survival (OS) were 72.9% and 74.1% respectively. Four-year OS for group A, B, C and stage I, II, III, IV was 100%, 73.2%, 56% (p = 0.005) and 100%, 90.5%, 72.7%, 56% (p = 0.02) respectively. Advanced disease and TLS were significant predictors of inferior EFS on multivariate analysis. We could achieve reasonably good survival in resource-limited settings with judicious use of resources like single-dose rasburicase and modified dose methotrexate.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Nirmal G, Thankamony P, Nair RA, et al. Resource-adapted strategies in the management of paediatric Burkitt lymphoma in low- and middle-income country setting and outcomes: An Indian centre experience. Br J Haematol. 2025. PMID: 40260587. doi:10.1111/bjh.20093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。